Diagnósticos da América (DASA3) Q2 2025 earnings summary

Executive summary

• Completed joint venture with Amil, forming Rede Américas, one of Brazil's largest hospital groups, and shifting strategic focus to diagnostics and operational excellence.

• Diagnostics is now the core business, serving 23 million patients and performing over 400 million exams annually, supported by over 40 brands.

• New leadership and organizational restructuring reduced SG&A expenses and improved efficiency through digitization and process optimization.

• Significant progress in digital transformation and ESG initiatives, enhancing patient and physician experience.

• Revenue and profitability were significantly impacted by the deconsolidation of hospital assets following the joint venture.

Financial highlights

• Consolidated gross revenue was R$2.7 billion, down 37% year-over-year due to deconsolidation; diagnostics segment revenue grew 6% year-over-year.

• Gross margin expanded by 0.9 p.p. to 29.7%; consolidated EBITDA rose 10% to R$738 million, with margin up to 29.9%.

• Net financial debt dropped to R$7.3 billion, down R$3.2–3.4 billion sequentially; leverage improved to 2.82x EBITDA, the lowest since 2021.

• Net result was a loss of R$173–176 million, mainly due to non-recurring items and tax impacts.

• Operating cash generation was R$44 million, with cash and equivalents at R$1.4 billion.

Outlook and guidance

• Focus remains on diagnostics, operational efficiency, and digital transformation to drive margin improvement and financial competitiveness.

• Ongoing optimization of SG&A, productivity gains, and disciplined capital allocation are expected to further improve margins and cash generation.

• Rede Américas integration and asset optimization are expected to yield synergies and operational improvements.